Literature DB >> 16082203

Stroma: tumor agonist or antagonist.

David A Proia1, Charlotte Kuperwasser.   

Abstract

Extensive research has been conducted over several decades understanding the genetic changes that occur in normal cells to promote them towards a transformed state. However, it is becoming increasingly apparent that carcinoma growth requires more complex interactions for development and progression. Since tissue epithelium is composed of highly specialized cells that orchestrate specific activities, their proper development and function is highly dependent on contextual signals from the stroma. As such, it is conceivable that carcinoma development should also parallel these needs. In light of our recent evidence combined with established work demonstrating the role of the tissue stromal environment in cancer development, it is evident that tissue stroma exhibits context specific tumor suppressive and tumor-promoting abilities that serve to regulate dysfunction and neoplastic growth of the epithelium.

Entities:  

Mesh:

Year:  2005        PMID: 16082203     DOI: 10.4161/cc.4.8.1903

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  27 in total

Review 1.  Targeting stroma to treat cancers.

Authors:  Boris Engels; Donald A Rowley; Hans Schreiber
Journal:  Semin Cancer Biol       Date:  2011-12-24       Impact factor: 15.707

2.  The tumor stromal microenvironment as modulator of malignant behavior.

Authors:  Charlotte Kuperwasser
Journal:  J Mammary Gland Biol Neoplasia       Date:  2010-12       Impact factor: 2.673

3.  Dynamic, long-term in vivo imaging of tumor-stroma interactions in mouse models of breast cancer using spinning-disk confocal microscopy.

Authors:  Andrew J Ewald; Zena Werb; Mikala Egeblad
Journal:  Cold Spring Harb Protoc       Date:  2011-02-01

4.  Three-dimensional cell culture model for measuring the effects of interstitial fluid flow on tumor cell invasion.

Authors:  Alimatou M Tchafa; Arpit D Shah; Shafei Wang; Melissa T Duong; Adrian C Shieh
Journal:  J Vis Exp       Date:  2012-07-25       Impact factor: 1.355

5.  RB in breast cancer: differential effects in estrogen receptor-positive and estrogen receptor-negative disease.

Authors:  Elizabeth A Musgrove; Robert L Sutherland
Journal:  Cell Cycle       Date:  2010-12-01       Impact factor: 4.534

6.  Prolonged exposure to extracellular lumican restrains pancreatic adenocarcinoma growth.

Authors:  X Li; Y Kang; D Roife; Y Lee; M Pratt; M R Perez; B Dai; E J Koay; J B Fleming
Journal:  Oncogene       Date:  2017-05-22       Impact factor: 9.867

7.  Transient tumor-fibroblast interactions increase tumor cell malignancy by a TGF-Beta mediated mechanism in a mouse xenograft model of breast cancer.

Authors:  Christina H Stuelten; Johanna I Busch; Binwu Tang; Kathleen C Flanders; Akira Oshima; Emily Sutton; Tatiana S Karpova; Anita B Roberts; Lalage M Wakefield; John E Niederhuber
Journal:  PLoS One       Date:  2010-03-23       Impact factor: 3.240

8.  Naïve rat umbilical cord matrix stem cells significantly attenuate mammary tumor growth through modulation of endogenous immune responses.

Authors:  Atsushi Kawabata; Naomi Ohta; Garret Seiler; Marla M Pyle; Susumu Ishiguro; Yong Qing Zhang; Kevin G Becker; Deryl Troyer; Masaaki Tamura
Journal:  Cytotherapy       Date:  2013-03-07       Impact factor: 5.414

9.  Lumican exhibits anti-angiogenic activity in a context specific manner.

Authors:  Bikram Sharma; Megan D Ramus; Christopher T Kirkwood; Emma E Sperry; Pao-Hsien Chu; Winston W Kao; Allan R Albig
Journal:  Cancer Microenviron       Date:  2013-06-18

10.  The normal breast microenvironment of premenopausal women differentially influences the behavior of breast cancer cells in vitro and in vivo.

Authors:  Jodie M Fleming; Tyler C Miller; Mariam Quinones; Zhen Xiao; Xia Xu; Matthew J Meyer; Erika Ginsburg; Timothy D Veenstra; Barbara K Vonderhaar
Journal:  BMC Med       Date:  2010-05-21       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.